NHL mAb / LifeArc - LARVOL DELTA

Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma (clinicaltrials.gov) - P2; N=20; Recruiting; Sponsor: Fred Hutchinson Cancer Research Center; Trial primary completion date: Oct 2015 ➔ Apr 2016

Trial primary completion date • Biosimilar

Motor Cortex Stimulation for Parkinson's Disease (clinicaltrials.gov) - P=N/A; N=13; Completed; Sponsor: Catholic University, Italy; Recruiting ➔ Completed; N=20 ➔ 13; Trial primary completion date: Jun 2010 ➔ Jun 2013

Enrollment change • Trial completion • Trial primary completion date • Biosimilar • Parkinson's Disease

A Study to Evaluate the Effectiveness of Voriconazole + Micafungin Versus Voriconazole Alone for Invasive Aspergillosis (clinicaltrials.gov) - P4; N=0; Withdrawn; Sponsor: Astellas Pharma Inc; N=350 ➔ 0

Enrollment change • Biosimilar

asn01-Dietary Intervention of Stress-Induced Neurovegetative Disorders With a Specific Amino Acid Composition (asn01) (clinicaltrials.gov) - P3; N=80; Completed; Sponsor: Kyberg Vital GmbH; Recruiting ➔ Completed; N=60 ➔ 80

Enrollment change • Trial completion • Biosimilar

Safety Study of Rituximab (Rituxan®) in Chronic Urticaria (clinicaltrials.gov) - P1/2; N=15; Terminated; Sponsor: Johns Hopkins University; Suspended ➔ Terminated; Trial primary completion date: Dec 2008 ➔ May 2007

Trial primary completion date • Trial termination • Biosimilar • Immunology • Inflammation